Goldstein D - Search Results

1

Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells.

Greiner JW, Guadagni F, Goldstein D, Smalley RV, Borden EC, Simpson JF, Molinolo A, Schlom J. Greiner JW, et al. Among authors: goldstein d. J Clin Oncol. 1992 May;10(5):735-46. doi: 10.1200/JCO.1992.10.5.735. J Clin Oncol. 1992. PMID: 1569446

2

Evidence for the elevation of serum carcinoembryonic antigen and tumor-associated glycoprotein-72 levels in patients administered interferons.

Greiner JW, Guadagni F, Goldstein D, Borden EC, Ritts RE Jr, Witt P, LoBuglio AF, Saleh MN, Schlom J. Greiner JW, et al. Among authors: goldstein d. Cancer Res. 1991 Aug 15;51(16):4155-63. Cancer Res. 1991. PMID: 1907881 Clinical Trial.

3

Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells.

Guadagni F, Schlom J, Johnston WW, Szpak CA, Goldstein D, Smalley R, Simpson JF, Borden EC, Pestka S, Greiner JW. Guadagni F, et al. Among authors: goldstein d. J Natl Cancer Inst. 1989 Apr 5;81(7):502-12. doi: 10.1093/jnci/81.7.502. J Natl Cancer Inst. 1989. PMID: 2466127

4

Phase II trial of carboplatin in soft-tissue sarcoma.

Goldstein D, Cheuvart B, Trump DL, Shiraki M, Comis RL, Tormey DC, Harris JE, Borden EC. Goldstein D, et al. Am J Clin Oncol. 1990 Oct;13(5):420-3. doi: 10.1097/00000421-199010000-00011. Am J Clin Oncol. 1990. PMID: 2220662 Clinical Trial.

5

A phase II study of crisnatol mesylate in patients with ovarian carcinoma.

Smalley RV, Goldstein D, Bulkowski D, Hannon C, Buchler D, Knudsen C, Tuttle RL. Smalley RV, et al. Among authors: goldstein d. Invest New Drugs. 1992 Jul;10(2):107-12. doi: 10.1007/BF00873127. Invest New Drugs. 1992. PMID: 1500264 Clinical Trial.

6

Absence of biological effects of orally administered interferon-beta ser.

Witt PL, Goldstein D, Storer BE, Grossberg SE, Flashner M, Colby CB, Borden EC. Witt PL, et al. Among authors: goldstein d. J Interferon Res. 1992 Dec;12(6):411-3. doi: 10.1089/jir.1992.12.411. J Interferon Res. 1992. PMID: 1289408

7

Effects of interferon beta ser and transforming growth factor beta on prostatic cell lines.

Goldstein D, O'Leary M, Mitchen J, Borden EC, Wilding G. Goldstein D, et al. J Urol. 1991 Oct;146(4):1173-7. doi: 10.1016/s0022-5347(17)38034-5. J Urol. 1991. PMID: 1895445

8

Effects of type I and II interferons on cultured human breast cells: interaction with estrogen receptors and with tamoxifen.

Goldstein D, Bushmeyer SM, Witt PL, Jordan VC, Borden EC. Goldstein D, et al. Cancer Res. 1989 May 15;49(10):2698-702. Cancer Res. 1989. PMID: 2469536

9

Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine.

Goldstein D, Sielaff KM, Storer BE, Brown RR, Datta SP, Witt PL, Teitelbaum AP, Smalley RV, Borden EC. Goldstein D, et al. J Natl Cancer Inst. 1989 Jul 19;81(14):1061-8. doi: 10.1093/jnci/81.14.1061. J Natl Cancer Inst. 1989. PMID: 2472488 Clinical Trial.

10

Human recombinant interferon-beta SER and tamoxifen: growth suppressive effects for the human breast carcinoma MCF-7 grown in the athymic mouse.

Gibson DF, Johnson DA, Goldstein D, Langan-Fahey SM, Borden EC, Jordan VC. Gibson DF, et al. Among authors: goldstein d. Breast Cancer Res Treat. 1993;25(2):141-50. doi: 10.1007/BF00662139. Breast Cancer Res Treat. 1993. PMID: 8347846

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,136 results

Search Page

Filters